Terms: = Breast cancer AND SMARCB1, Ini1, 6598, ENSG00000099956, Snr1, SNF5L1, RDT, BAF47, hSNFS, SNF5, INI1, Sfh1p, Q12824 AND Treatment
17 results:
1. The IL6/JAK/STAT3 signaling axis is a therapeutic vulnerability in smarcb1-deficient bladder cancer.
Amara CS; Kami Reddy KR; Yuntao Y; Chan YS; Piyarathna DWB; Dobrolecki LE; Shih DJH; Shi Z; Xu J; Huang S; Ellis MJ; Apolo AB; Ballester LY; Gao J; Hansel DE; Lotan Y; Hodges HC; Lerner SP; Creighton CJ; Sreekumar A; Zheng WJ; Msaouel P; Kavuri SM; Putluri N
Nat Commun; 2024 Feb; 15(1):1373. PubMed ID: 38355560
[TBL] [Abstract] [Full Text] [Related]
2. Immediate post-mastectomy prepectoral breast reconstruction with animal derived acellular dermal matrices: A systematic review.
Tellarini A; Garutti L; Corno M; Tamborini F; Paganini F; Fasoli V; Di Giovanna D; Valdatta L
J Plast Reconstr Aesthet Surg; 2023 Nov; 86():94-108. PubMed ID: 37716255
[TBL] [Abstract] [Full Text] [Related]
3. Genetic mutations in HER2-positive breast cancer: possible association with response to trastuzumab therapy.
Zakaria NH; Hashad D; Saied MH; Hegazy N; Elkayal A; Tayae E
Hum Genomics; 2023 May; 17(1):43. PubMed ID: 37202799
[TBL] [Abstract] [Full Text] [Related]
4. Ovarian epithelioid malignant peripheral nerve sheath tumor with EWSR1-CREM fusion: A case report and literature review.
Li S; Hong R; Wang X; Yang J
Int J Gynaecol Obstet; 2023 Nov; 163(2):521-527. PubMed ID: 37151162
[TBL] [Abstract] [Full Text] [Related]
5. Mitochondria-Targeted Nanosystem Enhances Radio-Radiodynamic-Chemodynamic Therapy on Triple Negative breast cancer.
Li J; You Z; Zhai S; Zhao J; Lu K
ACS Appl Mater Interfaces; 2023 May; 15(18):21941-21952. PubMed ID: 37099714
[TBL] [Abstract] [Full Text] [Related]
6. Management of patients with presumed germline pathogenic variant from tumor-only genomic sequencing: A retrospective analysis at a single facility.
Kawamura M; Shirota H; Niihori T; Komine K; Takahashi M; Takahashi S; Miyauchi E; Niizuma H; Kikuchi A; Tada H; Shimada M; Kawamorita N; Kanamori M; Sugiyama I; Tsubata M; Ichikawa H; Yasuda J; Furukawa T; Aoki Y; Ishioka C
J Hum Genet; 2023 Jun; 68(6):399-408. PubMed ID: 36804482
[TBL] [Abstract] [Full Text] [Related]
7. Development and validation of the PORTRET tool to predict recurrence, overall survival, and other-cause mortality in older patients with breast cancer in the Netherlands: a population-based study.
van der Plas-Krijgsman WG; Giardiello D; Putter H; Steyerberg EW; Bastiaannet E; Stiggelbout AM; Mooijaart SP; Kroep JR; Portielje JEA; Liefers GJ; de Glas NA
Lancet Healthy Longev; 2021 Nov; 2(11):e704-e711. PubMed ID: 36098027
[TBL] [Abstract] [Full Text] [Related]
8. [Comprehensive treatment options and influencing factors in elderly patients with breast cancer].
Lin Y; Xu Y; Cao X; Zhou XT; Zhou YD; Mao F; Wang CJ; Xu YL; Sun Q
Zhonghua Yi Xue Za Zhi; 2022 Feb; 102(6):428-434. PubMed ID: 35144343
[No Abstract] [Full Text] [Related]
9. Ipsilateral breast metastasis after axillary dissection caused by epithelioid sarcoma: a case report and pathological investigation.
Chen L; Wang L; Zhang X; Yao M; Fu P
Diagn Pathol; 2019 Oct; 14(1):111. PubMed ID: 31615564
[TBL] [Abstract] [Full Text] [Related]
10. Clinical Benefit to an Aurora A Kinase Inhibitor in a Patient with Metastatic Integrase Interactor 1-Deficient Carcinoma.
Karantanos T; Rooper L; Kang Y; Lin CT; Wenga P; Sagorsky S; Lauring J; Kang H
Oncologist; 2019 Feb; 24(2):146-150. PubMed ID: 30297384
[TBL] [Abstract] [Full Text] [Related]
11. ATR Is a Therapeutic Target in Synovial Sarcoma.
Jones SE; Fleuren EDG; Frankum J; Konde A; Williamson CT; Krastev DB; Pemberton HN; Campbell J; Gulati A; Elliott R; Menon M; Selfe JL; Brough R; Pettitt SJ; Niedzwiedz W; van der Graaf WTA; Shipley J; Ashworth A; Lord CJ
Cancer Res; 2017 Dec; 77(24):7014-7026. PubMed ID: 29038346
[TBL] [Abstract] [Full Text] [Related]
12. Genomic characteristics of trastuzumab-resistant Her2-positive metastatic breast cancer.
de Oliveira Taveira M; Nabavi S; Wang Y; Tonellato P; Esteva FJ; Cantley LC; Wulf GM
J Cancer Res Clin Oncol; 2017 Jul; 143(7):1255-1262. PubMed ID: 28247034
[TBL] [Abstract] [Full Text] [Related]
13. Safe and effective deodorization of malodorous fungating tumors using topical metronidazole 0.75 % gel (GK567): a multicenter, open-label, phase III study (rdt.07.SRE.27013).
Watanabe K; Shimo A; Tsugawa K; Tokuda Y; Yamauchi H; Miyai E; Takemura K; Ikoma A; Nakamura S
Support Care Cancer; 2016 Jun; 24(6):2583-90. PubMed ID: 26715293
[TBL] [Abstract] [Full Text] [Related]
14. cancer Signature Investigation: ERBB2 (HER2)-Activating Mutation and Amplification-Positive breast Carcinoma Mimicking Lung Primary.
Shih J; Bashir B; Gustafson KS; Andrake M; Dunbrack RL; Goldstein LJ; Boumber Y
J Natl Compr Canc Netw; 2015 Aug; 13(8):947-52. PubMed ID: 26285240
[TBL] [Abstract] [Full Text] [Related]
15. Tumor growth kinetics versus RECIST to assess response to locoregional therapy in breast cancer liver metastases.
Seyal AR; Parekh K; Velichko YS; Salem R; Yaghmai V
Acad Radiol; 2014 Aug; 21(8):950-7. PubMed ID: 24833565
[TBL] [Abstract] [Full Text] [Related]
16. Fulvestrant induces resistance by modulating GPER and CDK6 expression: implication of methyltransferases, deacetylases and the hSWI/SNF chromatin remodelling complex.
Giessrigl B; Schmidt WM; Kalipciyan M; Jeitler M; Bilban M; Gollinger M; Krieger S; Jäger W; Mader RM; Krupitza G
Br J Cancer; 2013 Nov; 109(10):2751-62. PubMed ID: 24169358
[TBL] [Abstract] [Full Text] [Related]
17. ini1 expression induces cell cycle arrest and markers of senescence in malignant rhabdoid tumor cells.
Reincke BS; Rosson GB; Oswald BW; Wright CF
J Cell Physiol; 2003 Mar; 194(3):303-13. PubMed ID: 12548550
[TBL] [Abstract] [Full Text] [Related]
